Core Insights - Evogene Ltd. and Lishan Biotech have entered into an exclusive worldwide licensing agreement for BMC128, a microbiome-based therapeutic aimed at enhancing anti-tumor immune activity [1] - BMC128 is currently in Phase 1 clinical trials, showing promising early results in renal cell carcinoma and non-small cell lung cancer, with a good safety profile and early signs of efficacy [1] - Lishan Biotech will take over global clinical development, manufacturing, and commercialization of BMC128, while Biomica will receive milestone payments and royalties [1] Company Overview - Evogene Ltd. specializes in computational chemistry and the generative design of small molecules for pharmaceutical and agricultural applications, utilizing its proprietary ChemPass AI™ technology [2] - Lishan Biotech focuses on innovative therapies for complex chronic diseases, employing unique technologies to address unmet medical needs in inflammation, oncology, and neurological disorders [4]

Core Insights - The partnership between Evogene Ltd. and Unravel Biosciences aims to address the unmet need for remyelination therapies in multiple sclerosis and other demyelinating conditions by leveraging advanced generative chemistry design and predictive platforms [1][2][3] Company Overview - Evogene Ltd. is a pioneering computational chemistry company specializing in the generative design of small molecules for pharmaceutical and agricultural industries [7] - Unravel Biosciences is a clinical-stage therapeutics company focused on advancing drugs for complex diseases through its Predictable Medicine platform [10] Collaboration Details - The collaboration seeks to design and validate brain-penetrant inhibitors targeting a novel demyelination target identified by Unravel's platform, aiming to create the first therapeutic capable of restoring myelin and improving neurological function [3][4] - Evogene's ChemPass AI will be utilized to advance novel drug targets for remyelination, optimizing drug candidates based on insights from Unravel's experimental systems [5][6] Scientific Approach - The partnership combines Evogene's state-of-the-art computational capabilities with Unravel's AI-powered predictive biology platform, utilizing RNA-based simulations and patient data to generate novel therapeutic insights [4][6] - The collaboration emphasizes a function-first discovery approach to gain biological insights from genetically defined demyelinating disorders, facilitating the translation of these insights into therapeutic applications [3][5] Market Need - Degenerative diseases, particularly demyelinating diseases like Multiple Sclerosis, affect hundreds of millions globally, with MS impacting approximately 3 million people [2] - Current therapies primarily focus on slowing disease progression rather than repairing existing damage, highlighting a significant unmet need for effective treatments that can reverse myelin loss [2]